# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000950170-25-083444
Filing Date
2025-06-09
Accepted
2025-06-09 07:29:37
Documents
13
Period of Report
2025-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | engn-20250604.htm iXBRL | 8-K | 53620
2 | EX-10.1 | engn-ex10_1.htm | EX-10.1 | 889273
3 | EX-10.2 | engn-ex10_2.htm | EX-10.2 | 33047
4 | GRAPHIC | img89482196_0.jpg | GRAPHIC | 884163
| Complete submission text file | 0000950170-25-083444.txt |  | 2476267

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | engn-20250604.xsd | EX-101.SCH | 45681
15 | EXTRACTED XBRL INSTANCE DOCUMENT | engn-20250604_htm.xml | XML | 6496

Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 251032837
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)